Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first ... Dermavant has high hopes for the cream because it provides an alternative to topical corticosteroid drugs, which ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The drug was the lead molecule in GSK's immuno-inflammation pipeline back ... compared to 6% of a placebo cream group. "Our participation in the revenue sale transaction reflects our confidence ...

One co-author reported receiving speaker's fees and other fees from GSK and Merck Sharp & Dohme ... including deli cheeses and meats, ice cream, fruits, packaged salad greens, enoki mushrooms ...

HUL's review decision follows Unilever PLC's earlier announcement about separating its global ice cream business ...

It's also known for its prolific use of mergers and acquisitions; the company is in the process of spinning of its ice cream business ... The Motley Fool recommends GSK, Philip Morris ...

While at GSK, Dr. Maeda-Chubachi was responsible for leading the Phase II clinical trial of eczema/psoriasis topical cream, Vtama. The clinical trial design and results led to the acquisition of ...